Abstract: The level of Th2 cells is increased in the lesions of atopic dermatitis (AD) and the Th2 cells can stimulate the secretion of IL-4 and IL-13. IL-4 and IL-13 can mediate the downstream signal transduction through the co-receptor IL-4Rα. A variety of new targeted immunosuppressive agents have been used in the clinical study of AD. Dupilumab is a monoclonal antibody to the anti-IL-4 receptor alpha subunit (IL-4Ralpha), which can inhibit IL-4 and IL-13 to bind to IL-4Ralpha and block its downstream signal transduction, resulting in the occurrence and control chronic inflammation. The update of the immunologic mechanism of dupilumab for treating AD is reviewed in this article.

Key words: atopic dermatitis, immune mechanism, biological agents, Dupilumab